Abstract
Pityriasis (tinea) versicolor and seborrheic dermatitis are two very common skin diseases. Pityriasis versicolor is a chronic superficial fungal disease usually located on the upper trunk, neck, or upper arms. In pityriasis versicolor, the lipophilic yeast Malassezia (also know as Pityrosporum ovale or P. orbiculare) changes from the blastospore form to the mycelial form under the influence of predisposing factors. The most important exogenous factors are high temperatures and a high relative humidity which probably explain why pityriasis versicolor is more common in the tropics. The most important endogenous factors are greasy skin, hyperhidrosis, hereditary factors, corticosteroid treatment and immunodeficiency. There are many ways of treating pityriasis versicolor topically. Options include propylene glycol, ketoconazole shampoo, zinc pyrithione shampoo, ciclopiroxamine, selenium sulfide, and topical antifungals. In difficult cases, short term treatment with fluconazole or itraconazole is effective and well tolerated. To avoid recurrence a prophylactic treatment regimen is mandatory.
Seborrheic dermatitis is characterized by red scaly lesions predominantly located on the scalp, face and upper trunk. There are now many studies indicating that Malassezia plays an important role in this condition. Even a normal number of Malassezia will start an inflammatory reaction. Mild corticosteroids are effective in the treatment of seborrheic dermatitis. However, the disease recurs quickly, often within just a few days. Antifungal therapy is effective in the treatment of seborrheic dermatitis and, because it reduces the number of Malassezia, the time to recurrence is increased compared with treatment with corticosteroids. Antifungal therapy should be the primary treatment of this disease.
Similar content being viewed by others
References
Gordon M.A. The lipophilic microflora of the skin. Mycologia 1951; 43: 524–534
Roberts S.O.B. Pityrosporum orbiculare: incidence and distribution on clinical normal skin. Br J Dermatol 1969; 81: 264–269
Faergemann J, Aly R, Maibach HI. Quantitative variations in distribution of Pityrosporum orbiculare on clinically normal skin. Acta Derm Venereol (Stockh) 983; 63: 346–8
Faergemann J., Fredriksson T. Age incidence of Pityrosporum orbiculare on human skin. Acta Derm Venereol (Stockh) 1980; 60: 531–533
Gueho E., Midgley G., Guillot J. The genus Malassezia with description of four new species. Antonie v Leuwenhoek 1996; 69: 337–355
Guillot J., Guého E., Lesourd M., et al. Identification of Malassezia species — a practical approach. J Mycol Méd 1996; 6: 103–110
Faergemann J. Lipophilic yeasts in skin disease. Semin Dermatol 1985; 4: 173–184
Faergemann J. Pityrosporum yeasts — what’s new? Mycoses 1997; 40 Suppl. 1: 29–32
Faergemann J. Pityrosporum infections. In: Elewski B.E., editor. Cutaneous fungal infections. New York: Igaku-Shoin, 1992: 69–83
Faergemann J. Tinea versicolor (Pityriasis versicolor). In: Demis D.J., editor. Clinical Dermatology. Philadelphia: Lippincott-Raven, 1995: 1–9
Faergemann J., Fredriksson T. Propylene glycol in the treatment of tinea versicolor. Acta Derm Venereol (Stockh) 1989; 60: 92–93
Fredriksson T. Topical treatment with BAY b 5097, a new broad spectrum antimycotic agent. Br J Dermatol 1972; 86: 628–630
Svejgaard E. Double-blind trial of miconazole in dermatomycosis. Acta Derma Venereol (Stockh) 1973; 53: 497–499
Swartz K.J., Moch T.H., Kenzelmann M. Poloklinische Prüfung von Econazole bei 594 Fallen von Hautmykosen. Dtsch Med Wochenschr 1975; 100: 1497–1500
Faergemann J., Fredriksson T. An open trial of the effect of a zinc pyrithione shampoo in tinea versicolor. Cutis 1980; 25: 667–669
Albright S.D., Hitch J.M. Rabbit treatment of tinea versicolor with selenium sulphide. Arch Dermatol 1966; 93: 460–461
Hernandez-Perez E. A comparison between one and two week’s treatment with bifonazole in pityriasis versicolor. J Am Acad Dermatol 1986; 14: 561–564
Savin R.C., Horwitz S.N. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J Am Acad Dermatol 1986; 15: 500–503
Aste N., Pau M., Pinna A.L., et al. Clinical efficacy and tolerability of terbinafine in patients with pityriasis versicolor. Mycoses 1991; 34: 353–357
Faergemann J., Hersle K., Nordin P. Pityriasis versicolor: clinical experience with Lamisil cream and Lamisil DermGel. Dermatol 1997; 194 Suppl. 1: 19–21
Vermeer B.J., Staats C.C.G. The efficacy of a topical application application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo controlled study. Dermatol 1997; 194 Suppl. 1: 22–24
Corte M., Jung K., Linker U., et al. Topical application of a 0.1% ciclopiroxolamine solution for the treatment of pityriasis versicolor. Mycoses 1989; 32: 200–203
Rekacewicz I., Guillaume J.C., Benkhraba F., et al. A double-blind placebo-controlled study of a 2 percent foaming lotion of ketoconazole in a single application in the treatment of pityriasis versicolor. Ann Dermatol Venereol 1990; 117: 709–711
Lange D.S., Richards H.M., Guarnieri J, et al. Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo- controlled study. J Am Acad Dermatol 1998; 39: 944–950
Jones H.E. Ketoconazole today. A review of clinical experience. Manchester, England: ADIS Press, 1987
Faergemann J., Djärv L.: Tinea versicolor: treatment and prophylaxis with ketoconazole. Cutis 1982; 30: 542–545
Hay R.J., Midgley G. Short course ketoconazole therapy in pityriasis versicolor. Clin Exp Dermatol 1984; 9: 571–573
Rausch L.J., Jacobs P.H. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis 1964; 34: 470–471
Shemer A., Nathansohn N., Kaplan B., et al. Itraconazole versus ketoconazole in the treatment of tinea versicolor. J Dermatol Treat 1999; 10: 19–23
Delescluse J. Itraconazole in tinea versicolor. A review. J Am Acad Dermatol 1990; 23: 551–554
Faergemann J. Treatment of pityriasis versicolor with itraconazole. A doubleblind placebo-controlled study. Mykoses 1988; 31: 377–379
Faergemann J. Treatment of pityriasis versicolor with a single dose of fluconazole. Acta Derm Venereol (Stockh) 1992; 72: 74–75
Amer M.A. Fluconazole in the treatment of tinea versicolor. Int J Dermatol 1997; 36: 938–946
Burton J.L., Holden C.A. Seborrhoeic dermatitis. In: Champion R.H., Burton J.L., Burna D.A., et al., editors. Textbook of Dermatology (ed 6). Oxford: Blackwell Scientific Publications, 1998: pp 638–643
Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Dactacort), miconazole and hydrocrotisone. Br J Dermatol 1986; 114: 695–700
Bergbrant I.-M. Seborrhoeic dermatitis and Pityrosporum ovale: cultural, immunological and clinical studies. Acta Derm Venereol Suppl (Stockh) 1991; 167: 1–36
Sohnle P.G., Collins-Lech C. Activation of complement by Pityrosporum orbiculare. J Invest Dermatol 1983; 80: 93–97
Midgley G., Hay R.J. Serological responses to Pityrosporum (Malassezia) in seborrhoeic dermatitis demonstrated by ELISA and Western blotting. Bull Soc Fr Mycol Méd 1988; 17: 267–276
Neuber K., Kröger S., Gruseck E., et al. Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN?) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch Dermatol Res 1996; 288: 532–536
Wikler J.R., Trago E., de Haan P., et al. Cell-mediated deficiency to Pityrosporum orbiculare in patients with seborrhoeic dermatitis [abstract]. ESDR-JSID-SID Tricontinental Meeting; 1989 Apr 26-30; Washington DC
Ashbee H.R., Ingham E., Holland K.T, et al. Cell-mediated immune responses to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrhoeic dermatitis and controls. Exp Dermatol 1994; 3: 106–112
Bergbrant I.-M., Andersson B., Faergemann J. Cell-mediated immunity to Pityrosporum ovale in patients with seborrhoeic dermatitis and pityriasis versicolor. Cin Exp Dermatol 1999; 24: 402–406
Pearry M.E., Sharpe G.R. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 1998; 139: 254–263
Bergbrant I.-M., Johansson S., Robbins D., et al. An immunological study in patients with seborrhoeic dermatitis. Clin Exp Dermatol 1991; 16: 331–338
Kieffer M., Bergbrant I.-M., Faergemann J., et al. Skov patients with atopic dermatitis and seborrhoeic dermatitis. J Am Acad Dermatol 1990; 22: 739–742
Kesavan S., Walters C.E., Holland K.T, et al. The effects of Malassezia on pro-inflammatory cytokine production by human peripheral blood mononuclear cells in vitro. Med Mycol 1998; 36: 97–106
Piérard-Franshimont C., Arrese J.E., Piérard G.E. Immunohistochemical aspects of the link between Malassezia ovalis and seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1995; 4: 14–49
Romani L., Bistoni F., Puccetti P. Initiation of T-helper cell immunity to Candida albicans by IL-12: the role of neutrophils. Chem Immunol 1997; 68: 110–135
Gulay Z., Imir T. Anti-candidial activity of natural killer (NK) an lymphokine activated killer (LAK) lymphocytes in vitro. Immunobiol 1996; 95: 220–230
Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984; 111: 235–242
Skinner R.B., Noah P.W., Taylor R.M., et al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol 1985; 2: 852–857
Faergemann J. Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. Acta Dermato Venereol (Stockh) 1990; 70: 171–172
Ford G.P., Farr P.M., Ive F.A., et al. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984; 111: 603–607
Stratigos I.D., Katamboas A., Antoniu C.H., et al. Ketoconazole 2% cream versus 1% hydrocortisone cream in the treatment of seborrhoeic dermatitis: a doubleblind comparative study. J Am Acad Dermatol 1988; 19: 850–853
Marks R., Pears A.D., Walker A.P. The effects of a shampoo containing zinc pyrithione on the control of dandruff. Br J Dermatol 1985; 112: 415–422
Faergemann J. Propylene glycol in the treatment of seborrheic dermatitis of the scalp: a double-blind study. Cutis 1988; 42: 69–71
Faergemann J. Treatment of seborrhoeic dermatitis with bifonazole. Mycoses 1989; 32: 309–311
Shuttleworth D., Squire R.A., Boorman G.C., et al. Comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) or ketoconazole (2%; Nizoral) for the control of dandruff/seborrhoeic dermatitis. J Dermatol Treat 1998; 9: 157–162
Zeharia A., Mimouni M., Fogel D. Treatment with bifonazole shampoo for scalp seborrhea in infants and young children. Ped Dermatol 1996; 13: 151–153
Pari T., Pulimood S., Jacob M., et al. Randomised double blind controlled trial of 2% ketoconazole cream versus 0.05% clobetasol 17-butyrate cream in seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1998; 10: 89–90
Veen A.J., Prevoo R.L.M.A., Velders A.J., et al. Betamethasone-17-valerate compared with ketoconazole for topical treatment of seborrhoeic dermatitis of the scalp in adults. J Dermatol Treat 1998; 9: 239–245
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Faergemann, J. Management of Seborrheic Dermatitis and Pityriasis Versicolor. Am J Clin Dermatol 1, 75–80 (2000). https://doi.org/10.2165/00128071-200001020-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200001020-00001